Indegene Stock Performance
|
|
|
Indegene Company background
Founded in: 1998
Indegene Limited was incorporated as Indegene Lifesystems Private Limited at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to Indegene Private Limited and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to Indegene Limited on November 17, 2022.The Company is a digitalfirst life sciences commercialization company, enabling biopharmaceutical, emerging biotech, and medical device companies to develop, launch, and scale the impact of their products with greater speed, precision, and efficiency. As a specialized company, it combine healthcare domain expertise, fitforpurpose technology, and an agile operating model to solve the most complex problems in the healthcare industry.Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a digital first approach for optimizing the lastmile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analytics in helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.The Company acquired Cult Health, a fullservice healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.The Company launched Invisage, an AIenabled hybrid omnichannel sales and marketing platform in 2023. The Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.In 2024, the Company acquired a controlling stake in Trilogy Writing Consulting GmbH, a medical writing consultancy firm. It set up a new global delivery center in Hyderabad. In FY 2025, the Company launched a new center in Hyderabad to strengthen the business operations. In Europe, it launched a new entity in Spain and a new center in London. Indegenes Europebased clients became as a strategic hub for consulting and commercialization solutions and modernize their operations with an AIfirst approach. Further, the Company acquired MJL, a UKbased specialized healthcare advertising and communications agency. It launched Cortex, a fitforpurpose Generative AI platform for the life sciences industry.
Indegene Financial Highlights
Indegene reported a Q2 FY 2025-26
revenue of ₹804.2 crore,
up 10.5% YoY,
with net profit increased
20.8% to ₹102.1 crore. For the full year FY2025–2026, revenue
reached ₹2946.5 crore and profit touched at
₹406.7 crore.
Indegene Share Price Today
As of 8 Nov 2025, Indegene share price is ₹523.1. The stock opened at ₹527 and had closed at ₹530.2 the previous day. During today’s trading session, Indegene share price moved between ₹507.70 and ₹528.65, with an average price for the day of ₹518.17. Over the last 52 weeks, the stock has recorded a low of ₹499.00 and a high of ₹735.00. In terms of performance, Indegene share price has declined by 5.6% over the past six months and has declined by 0.2% over the last year.
Indegene Fundamental
Market Cap (in crs)
12,561.70
Face Value
2
Turnover (in lacs)
2,673.67
Key Metrics
Qtr Change %
Near 52W Low of ₹499.00
-9.2
Dividend yield 1yr %
Below industry Median
0.4
Indegene Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Indegene Quarterly Revenue
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
804.2 Cr | 760.8 Cr | 755.6 Cr | 720.4 Cr | 686.8 Cr |
Indegene Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
2946.5 Cr | 2665.9 Cr | 2364.1 Cr | 1690.5 Cr | 996.92 Cr |
Indegene Quarterly Net Profit/Loss
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
102.1 Cr | 116.4 Cr | 117.6 Cr | 109.7 Cr | 91.7 Cr |
Indegene Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
406.7 Cr | 336.7 Cr | 266.1 Cr | 162.82 Cr | 185.88 Cr |
Indegene Result Highlights
Result Summary
-
Indegene Ltd reported a 5.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.3%.
-
Its expenses for the quarter were up by 9.5% QoQ and 18.3% YoY.
-
The net profit decreased 12.3% QoQ and increased 11.3% YoY.
-
The earnings per share (EPS) of Indegene Ltd stood at 4.23 during Q2 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Indegene Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
523.1
Current Price
Day EMA5
532.70
Day EMA10
537.90
Day EMA12
539.40
Day EMA20
544.20
Day EMA26
546.90
Day EMA50
554.10
Day EMA100
561.80
Day EMA200
571.40
Day SMA5
533.60
Day SMA10
539.70
Day SMA20
543.60
Day SMA30
551.50
Day SMA50
556.30
Day SMA100
563.50
Day SMA150
568.60
Day SMA200
570.50
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 265089 Rs | 558318 Rs |
Week Rs | 145638 Rs | 303643 Rs |
Month Rs | 250126 Rs | 391529 Rs |
Resistance & Support
519.82
Pivot
Resistance
First Resistance
531.93
Second Resistance
540.77
Third Resistance
552.88
Support
First Support
510.98
Second support
498.87
Third Support
490.03
Relative Strength Index
35.60
Money Flow Index
68.47
MACD
-7.56
MACD Signal
-6.06
Average True Range
13.62
Average Directional Index
17.54
Rate of Change (21)
-5.20
Rate of Change (125)
-5.48
Indegene Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6,190.30 | 6,772.19 | 4810.2 | 6725 | 6,206.90 | -3.27% | -2.55% | 11.05% | 14.11% | 294.36% | 0.16% | 30.72 | 89.55 | 6.23 | |
3,096.70 | 25,942.76 | 2293.55 | 3540 | 3,108.00 | -1.24% | -1.59% | 8.57% | 0.80% | 17.96% | 0.77% | 49.09 | 89.55 | 11.09 | |
1,391.10 | 7,380.33 | 658 | 1474 | 1,324.20 | -0.44% | 14.12% | 50.78% | 43.81% | 108.87% | 1.51% | 61.53 | 89.55 | 14.31 | |
1,963.90 | 10,177.32 | 1315 | 2263 | 2,005.80 | -0.33% | -6.81% | 15.82% | -7.01% | 13.89% | 0.00% | 76.01 | 89.55 | 7.64 | |
1,023.60 | 10,514.92 | 740 | 1275 | 1,018.05 | 3.54% | 2.32% | 1.71% | -0.16% | 113.54% | 0.20% | 70.63 | 89.55 | 12.43 | |
1,660.20 | 28,499.52 | 1236.8 | 2189 | 1,667.50 | 0.87% | 7.96% | 14.04% | 0.00% | 0.00% | 0.00% | 65.72 | 29.36 | 19.27 |
Indegene Share Price FAQs
What is Share Price of Indegene ?
Indegene share price is ₹523.1 in NSE and ₹523.15 in BSE as on 7/11/2025.
How has Indegene shares performed in the past ?
Indegene share price in the past 1-year return was -25.27. The Indegene share hit a 1-year low of Rs. 499 and a 1-year high of Rs. 735.
What is the market cap of Indegene ?
The market cap of Indegene is Rs. 12561.7 Cr. as of 7/11/2025.
What is the current P/E ratio of Indegene ?
The PE ratios of Indegene is 60.06 as of 7/11/2025.
What is the current PB ratio of Indegene ?
The PB ratios of Indegene is 6.4 as of 7/11/2025
What is the Mutual Fund shareholding in Indegene ?
The Mutual Fund Shareholding in Indegene was 3.07% at the end of 7/11/2025.
How to buy Indegene shares?
You can easily buy Indegene shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Indegene ?
The 52-week high and low of Indegene share price is ₹735 and ₹499 as of 7/11/2025.
What is the EPS of Indegene ?
The earnings per share (EPS) of Indegene stood at 4.23 during Q2 FY 2025-26.
Please be aware that Indegene stock prices are subject to continuous fluctuations due to various factors.
Invest in Indegene